Patients with Tönnis grade 1 who underwent arthroscopic treatment of femoroacetabular impingement and labral tears experienced similar, durable improvements compared with patients with Tönnis grade 0, according to results.
Benjamin G. Domb
“There is a paucity of literature regarding midterm outcomes of hip arthroscopy for the treatment of [femoroacetabular impingement] FAI and labral tear in patients with mild [osteoarthritis] OA,” Benjamin G. Domb, MD, told Healio.com/Orthopedics. “This study demonstrates the outcomes of this group of patients and shows the outcomes compared to a matched non-arthritic control group.”
Domb and his colleagues prospectively collected data on 292 hips that underwent arthroscopic surgery for femoroacetabular impingement and labral tears and had either Tönnis grade 1 (n=85) or Tönnis grade 0 (n=207). Researchers also collected preoperative patient-reported outcome scores, including the modified Harris Hip score, non-arthritic hip score, hip outcome score–sport-specific subscale and VAS for pain. In a further analysis, researchers compared 62 hips with Tönnis grade 1 with 62 hips with Tönnis grade 0 that were matched for age, BMI, sex, labral treatment and capsular treatment.
Results showed significant improvements in all patient-reported outcomes and VAS scores for patients with Tönnis grade 1 at 5-year follow-up. Researchers noted an overall satisfaction score of 8.2. According to results, survivorship rate at 5 years with respect to conversion to total hip arthroplasty was 69.4% and 88.4% in the Tönnis grade 1 group and Tönnis grade 0 group, respectively.
When comparing the two groups, researchers found improvements in all patient-reported outcome and VAS scores from preoperatively to postoperatively in both groups, as well as no significant differences between preoperative or postoperative scores or survivorship. – by Casey Tingle
Disclosures: Domb reports he receives personal fees and other support from Arthrex, Pacira and Stryker; receives other support from Breg and ATI; and receives personal fees from Orthomerica, DJO Global, Amplitude and Medacta. Please see the full study for a list of all other authors’ relevant financial disclosures.